SCHEMBL22459586

SCHEMBL22459586

CCOP(=O)(OCC)Oc1cc(OC)c2c(=O)cc(-c3ccc(OC)c(-c4c(OP(=O)(OCC)OCC)cc(OC)c5c(=O)cc(-c6ccc(OC)cc6)oc45)c3)oc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 2/20 0.53
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ HBB P68871 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ MAOB P27338 7/20 0.45
▸ MAOA P21397 3/20 0.45
▸ CYP3A4 P08684 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ APP P05067 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22459582 0.94 ABCB1 (0.54) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL22459984 0.90 MAPT (0.61) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL27350540 0.85 ABCB1 (0.71) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL22460005 0.78 MEN1 (0.70) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL22459378 0.77 MAPT (0.65) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL20534814 0.77 MEN1 (0.54) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL20534813 0.76 MAPT (0.64) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL20535339 0.76 MAPT (0.67) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL22459583 0.76 MEN1 (0.69) ABCB1MEN1KMT2AKDM4EMAPT
SCHEMBL22812901 0.74 MEN1 (0.64) MEN1KMT2AKDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11110105-B2 Compounds, composition and uses thereof for treating cancer INSTITUT GUSTAVE ROUSSY (FR) 2021-09-07 — — US disclosed
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2020-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER PTPRC, PTPRS, PTPRCAP ABCB1 1217/4885MEN1 2190/4885KMT2A 3703/4885
US-11110105-B2 Compounds, composition and uses thereof for treating cancer PTPRC, PTPRS, PTPRCAP ABCB1 1217/4885MEN1 2190/4885KMT2A 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback